Improving Early Detecti on of Melanoma

By Emerald Medical Applications

2

Forward Looking Statements

The Company believes that some of the statements included in this release may

constitute "forward-looking statements" within the meaning of Section 27A of the

Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as

that term is defined in the Private Litigation Reform Act of 1995. Such statements

involve a number of risks and uncertainties such as competitive factors,

technological development, market demand and the Company’s ability to obtain

contracts and accurately estimate net revenues due to variability in size, scope and

duration of contracts. Further information on potential factors that could affect the

Company’s financial results, can be found in the Company’s various filings with the

Securities and Exchange Commission (SEC).

3

Emerald Medical Applications

Startup nation spirit

Project launch 2013

16 Team members Edge of technology

260 years - vast experience

CEO – Lior Wayn VP Product – Adi Zamir VP R&D Itzik Hanan CFO – Oded Gilboa

4

R&D project with an EU partners

3rd place!!!

Awards

5

6

Market$25 B

Cost of treatmentUSA

5 M treated, $8 B in treatment cost / year

UK$600 M treatment

cost / year

Germany“Skin Cancer is the

nation’s most common cancer”

420 M People at high risk of Melanoma$150,000 per patient - Direct costs for the

treatment

Australia1 of 7

7

SolutionEmerald Derma Compare

EDC

8

……. For saving lives !!!

N1 (x, y, z,…)

N1 (x, y, z,…)

9

It’s all about comparison

1998 2008

2003 2012

2008 2014

TBP 2015 2016

10

SLR Camera MobileAPP Google Glass mHealth

Take a set of TBP photos

11

DermaCompare App

12

Doctor Clinique

13

Total body photography

Alert !

14

15

Crowd sourcing & Big data

16

Improving the Golden Standard

Supported by Chief Scientists

Multidimensional Database

Augmented Reality & Google Glass

Cloud SaaS

DermaCompare

Artificial Intelligence & Machine Learning

Automated Comparison

Tele medicine

17

SOLUTION – Key Benefits

01

Cloud / SaaS

02

Low cost

03

More accurate

04

Less overall costsof treatment

05

Serves morepatients

06

Higher turnoverfor physicians

18

Go to market

HMO’sClinics Hospitals InsuranceCompanies

PublicHealth

19

Business model

per patient

$95 Flat fee

Direct costs for the treatment-

$150,000

Per patient per year

20

Emerald’s journey

2013

BootstrappingAnd POCs

2014

Doctor Module

11/2014

Investment & Public

03/2015

03/2015

G2M in Germany

Mobile APP

21

Going Public

Emerald signed a share exchange agreement

with Zaxis international Inc ( OTCQB : ZXSI)

that will result in Emerald becoming Zaxis's

fully owned subsidiary.

The reverse merger is expected to be completed

within

60-90 days

22

Early Detection of skin Cancer

ABCof saving lives!!

23

Lior Wayn – CEO Adi Zamir- VP

Skype: LiorWayn Adi_Zamir

lior@dermacompare.com adi@dermacompare.com

+972-50-6816300 +972-54-4861247

www.facebook.com/EmeraldDC